{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:29:57Z","timestamp":1789414197193,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["HORIZON-HLTH-2022-TOOL-11-01"],"award-info":[{"award-number":["HORIZON-HLTH-2022-TOOL-11-01"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["101095146"],"award-info":[{"award-number":["101095146"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We investigated circulating protein profiles and molecular pathways among various chronic kidney disease (CKD) aetiologies to study its underlying molecular heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a proteomic biomarker analysis in the DAPA-CKD trial recruiting adults with and without type 2 diabetes with an estimated glomerular filtration rate of 25\u201375\u00a0ml\/min\/1.73\u00a0m2 and a urine albumin:creatinine ratio of 200\u20135000\u00a0mg\/g. A total of 2926 proteins were analysed by Olink Explore in plasma samples collected at baseline. Proteins associated with diabetic kidney disease (DKD), glomerulonephritis (GN) and hypertensive nephropathy were identified using linear models to compare each CKD aetiology against the others.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 4304 randomized participants, baseline plasma proteomic profiles were available for 2485 participants (57.7%). Compared with patients without DKD, those with DKD had higher plexin B2 (PLXNB2; log2 fold difference 0.34, P\u00a0&amp;lt;\u00a0.001), vascular adhesion protein-1 (VAP-1; log2 fold difference 0.34, P\u00a0&amp;lt;\u00a0.001) and kidney injury molecule-1 (KIM-1; log2 fold difference 0.79, P\u00a0&amp;lt;\u00a0.001), suggesting involvement of immune activation, oxidative stress and tubular damage. Based on these molecular pathways, interleukin-6 was identified as an upstream regulator in DKD. In an external database of the Kidney Precision Medicine Project, PLXNB2 and VAP-1 were also elevated in DKD compared with non-DKD (log2 fold difference 0.41 and 0.42, respectively). In GN, levels of nephrin, a key slit diaphragm protein, were lower (log2 fold difference \u22120.27, P\u00a0&amp;lt;\u00a0.001). Furthermore, receptor for advanced glycation end products (log2 fold difference 0.28, P\u00a0&amp;lt;\u00a0.001) and heparan sulphate 6-O-sulfotransferase 2 (log2 fold difference 0.2, P\u00a0&amp;lt;\u00a0.05) were higher, suggesting glycocalyx disruption and inflammation. In hypertensive nephropathy, epiregulin, a member of the epidermal growth factor family, was higher compared with other CKD aetiologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study highlights distinct proteomic differences in patients with DKD, GN and hypertensive nephropathy. These findings may aid in unravelling the heterogeneous underlying molecular phenotype of CKD pathophysiology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf180","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:24:38Z","timestamp":1757330678000},"page":"545-555","source":"Crossref","is-referenced-by-count":3,"title":["Protein profiles and associated biological pathways among different aetiologies of chronic kidney disease: new insights from DAPA-CKD"],"prefix":"10.1093","volume":"41","author":[{"given":"M Andr\u00e9","family":"de la Rambelje","sequence":"first","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Department of Clinical Pharmacy and Pharmacology, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris E","family":"Beldhuis","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Department of Cardiology, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J L","family":"Heerspink","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Department of Clinical Pharmacy and Pharmacology, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Greasley","sequence":"additional","affiliation":[{"name":"Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Agren","sequence":"additional","affiliation":[{"name":"Quantitative Biology and Data Science, BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hammarstedt","sequence":"additional","affiliation":[{"name":"Late-stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C David","family":"Sj\u00f6str\u00f6m","sequence":"additional","affiliation":[{"name":"Late-stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A","family":"Voors","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Department of Cardiology, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Jongs","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Department of Clinical Pharmacy and Pharmacology, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"2026022705015089600_bib1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mcna.2012.10.001","article-title":"Epidemiology of diabetic kidney disease","volume":"97","author":"Reutens","year":"2013","journal-title":"Med Clin North Am"},{"issue":"Suppl 1","key":"2026022705015089600_bib2","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2018.01.002","article-title":"US Renal Data System 2017 annual data report: epidemiology of kidney disease in the United States","volume":"71","author":"Saran","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"3 Suppl 1","key":"2026022705015089600_bib3","doi-asserted-by":"publisher","first-page":"A8","DOI":"10.1053\/j.ajkd.2022.12.001","article-title":"US Renal Data System 2022 annual data report: epidemiology of kidney disease in the United States","volume":"81","author":"Johansen","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"1 Suppl 1","key":"2026022705015089600_bib4","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2012.11.031","article-title":"US Renal Data System 2012 annual data report","volume":"61","author":"Collins","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2026022705015089600_bib5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2010.154","article-title":"Epidemiology of hypertensive kidney disease","volume":"7","author":"Udani","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2026022705015089600_bib6","doi-asserted-by":"publisher","first-page":"2100170","DOI":"10.1002\/pmic.202100170","article-title":"Stability and reproducibility of proteomic profiles in epidemiological studies: comparing the Olink and SOMAscan platforms","volume":"22","author":"Haslam","year":"2022","journal-title":"Proteomics"},{"key":"2026022705015089600_bib7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd892","article-title":"The druggable genome","volume":"1","author":"Hopkins","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"2026022705015089600_bib8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2026022705015089600_bib9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026022705015089600_bib10","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2026022705015089600_bib11","article-title":"Kidney Precision Medicine Project"},{"key":"2026022705015089600_bib12","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1038\/s41467-022-34754-z","article-title":"Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population","volume":"13","author":"Zaghlool","year":"2022","journal-title":"Nat Commun"},{"key":"2026022705015089600_bib13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.diff.2010.10.001","article-title":"Sema4C-Plexin B2 signalling modulates ureteric branching in developing kidney","volume":"81","author":"Per\u00e4l\u00e4","year":"2011","journal-title":"Differentiation"},{"key":"2026022705015089600_bib14","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2337\/db19-1070","article-title":"Circulating protein signatures and causal candidates for type 2 diabetes","volume":"69","author":"Gudmundsdottir","year":"2020","journal-title":"Diabetes"},{"key":"2026022705015089600_bib15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/jdi.14209","article-title":"The role of vascular adhesion protein-1 in diabetes and diabetic complications","volume":"15","author":"Yen","year":"2024","journal-title":"J Diabetes Invest"},{"key":"2026022705015089600_bib16","doi-asserted-by":"publisher","first-page":"e0147981","DOI":"10.1371\/journal.pone.0147981","article-title":"Serum vascular adhesion protein-1 predicts end-stage renal disease in patients with type 2 diabetes","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"2026022705015089600_bib17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-8587(18)30289-4","article-title":"Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial","volume":"6","author":"de Zeeuw","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026022705015089600_bib18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2026022705015089600_bib19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/eurheartj\/eht454","article-title":"Advanced glycation endproducts and plaque instability: a link beyond diabetes","volume":"35","author":"Paneni","year":"2014","journal-title":"Eur Heart J"},{"key":"2026022705015089600_bib20","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"2026022705015089600_bib21","doi-asserted-by":"publisher","first-page":"F111","DOI":"10.1152\/ajprenal.00173.2005","article-title":"Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier","volume":"290","author":"Jeansson","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026022705015089600_bib22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.kint.2018.08.024","article-title":"Aldosterone induces albuminuria via matrix metalloproteinase\u2013dependent damage of the endothelial glycocalyx","volume":"95","author":"Butler","year":"2019","journal-title":"Kidney Int"},{"key":"2026022705015089600_bib23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s40001-023-01431-w","article-title":"Role of advanced glycation end products in diabetic vascular injury: molecular mechanisms and therapeutic perspectives","volume":"28","author":"Liu","year":"2023","journal-title":"Eur J Med Res"},{"key":"2026022705015089600_bib24","doi-asserted-by":"publisher","first-page":"100121","DOI":"10.1016\/j.mbplus.2022.100121","article-title":"Alterations in heparan sulfate proteoglycan synthesis and sulfation and the impact on vascular endothelial function","volume":"16","author":"Pretorius","year":"2022","journal-title":"Matrix Biol Plus"},{"key":"2026022705015089600_bib25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13049-016-0239-y","article-title":"The endothelial glycocalyx and its disruption, protection and regeneration: a narrative review","volume":"24","author":"Sch\u00f6tt","year":"2016","journal-title":"Scand J Trauma Resusc Emerg Med"},{"key":"2026022705015089600_bib26","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa2314471","article-title":"Autoantibodies targeting nephrin in podocytopathies","volume":"391","author":"Hengel","year":"2024","journal-title":"N Engl J Med"},{"key":"2026022705015089600_bib27","doi-asserted-by":"publisher","first-page":"7495","DOI":"10.1074\/jbc.270.13.7495","article-title":"Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes","volume":"270","author":"Isobe","year":"1995","journal-title":"J Biol Chem"},{"key":"2026022705015089600_bib28","doi-asserted-by":"publisher","first-page":"F219","DOI":"10.1152\/ajprenal.00082.2007","article-title":"Epiregulin promotes proliferation and migration of renal proximal tubular cells","volume":"293","author":"Zhuang","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026022705015089600_bib29","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1167\/iovs.11-8869","article-title":"Important role of epiregulin in inflammatory responses during corneal epithelial wound healing","volume":"53","author":"Zhang","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026022705015089600_bib30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcdb.2014.03.005","article-title":"Epiregulin: roles in normal physiology and cancer","volume":"28","author":"Riese","year":"2014","journal-title":"Semin Cell Dev Biol"},{"key":"2026022705015089600_bib31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.freeradbiomed.2018.12.002","article-title":"Peroxiredoxin 3 deficiency accelerates chronic kidney injury in mice through interactions between macrophages and tubular epithelial cells","volume":"131","author":"Hwang","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"2026022705015089600_bib32","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1373\/clinchem.2016.254649","article-title":"Waste, leaks, and failures in the biomarker pipeline","volume":"63","author":"Ioannidis","year":"2017","journal-title":"Clin Chem"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf180\/64222493\/gfaf180.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/3\/545\/64222493\/gfaf180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/3\/545\/64222493\/gfaf180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:01:56Z","timestamp":1772186516000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/3\/545\/8249290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,8]]},"published-print":{"date-parts":[[2026,2,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf180","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,9,8]]}}}